The agency’s decision supports broader access to a minimally invasive treatment for patients with severe tricuspid ...

The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after implant, according to an update from the TRISCEND II trial. Among study ...

St. Rita’s Medical Center now offers non-surgical treatment for tricuspid regurgitation or leaky heart valve, a condition in ...

In the midst of transformative transcatheter approaches to repair diseased aortic and mitral valves, the tricuspid valve has been overshadowed, according to Michael E. Bowdish, MD, vice chair of ...

Transcatheter tricuspid repair reduced valve regurgitation and improved quality of life at 1 year even for the sickest patients, but mortality remained high, new analysis of TRILUMINATE trial shows.

Hybrid imaging approach for guidance of transcatheter tricuspid valve replacement with Evoque system for lead-associated type B atrial tricuspid valve regurgitation, Journal of Cardiology Cases ...

If a person’s heart valves become damaged, they may benefit from having heart valve replacement surgery. Doctors may assess a person's suitability for the surgery. Learn more here.

Joan Mertz, 83, became the first patient in the state to undergo an artificial heart valve replacement without the need for open-heart surgery. Latest U.S.

A team at HonorHealth Scottsdale (Ariz.) Shea Medical Center performed the state’s first tricuspid valve replacement using the Edwards Lifesciences’ Evoque system outside of a clinical trial.

Laplace Interventional, a US-based medical device company focusing on transcatheter valve technology, recently announced the successful completion of a Series C funding round worth $22 million.

Source Reference: Hahn RT, et al "Transcatheter valve replacement in severe tricuspid regurgitation" N Engl J Med 2024; DOI: 10.1056/NEJMoa2401918. Share on Facebook. Opens in a new tab or window ...